Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Jianwei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3753-7659; OpenAlex author ID A5100326966. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 15

  1. Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsatur… Last author DOI 10.1186/s13062-023-00421-6↗
  2. Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. First author DOI 10.1016/j.pan.2021.04.007↗
  3. Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin. Co-author DOI 10.1186/s12885-020-07556-z↗
  4. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  5. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Co-author DOI 10.2147/cmar.s162980↗
  6. Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis. Co-author DOI 10.2169/internalmedicine.1114-18↗
  7. Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients… Co-author DOI 10.7717/peerj.4893↗
  8. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. Co-author DOI 10.1038/s41598-017-08794-1↗
  9. Body mass index does not affect the survival of pancreatic cancer patients. Co-author DOI 10.3748/wjg.v23.i34.6287↗
  10. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. First author DOI 10.1097/fpc.0000000000000241↗
  11. Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: Retrospective cohort study, 7-year ex… Co-author DOI 10.1097/md.0000000000004861↗
  12. Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer. Co-author PMID 25932223↗
  13. [Application value of core needle biopsy technique in the pathological diagnosis of locally advanced pancreatic cancer]. First author PMID 26081211↗
  14. [Early complications of intra-operative radiotherapy in locally advanced pancreatic cancer]. Co-author PMID 25241794↗
  15. [Value of intraoperative radiotherapy in the treatment of locally advanced pancreatic cancer]. Co-author PMID 21418868↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yingtai Chen · 9 shared papers, 2014–2019 · strength 0.61
  2. Chengfeng Wang · 6 shared papers, 2017–2023 · strength 0.59
  3. Shuisheng Zhang · 6 shared papers, 2016–2023 · strength 0.53
  4. Xu Che · 8 shared papers, 2011–2019 · strength 0.43
  5. Hu Ren · 3 shared papers, 2020–2023 · strength 0.39
  6. Chengfeng Wang · 4 shared papers, 2014–2017 · strength 0.22
  7. Zongting Gu · 2 shared papers, 2020–2021 · strength 0.22
  8. Guotong Qiu · 2 shared papers, 2020–2021 · strength 0.22
  9. Chengfeng Wang · 3 shared papers, 2011–2021 · strength 0.21
  10. Guang Li · 2 shared papers, 2019–2021 · strength 0.19
  11. Qifeng Xiao · 1 shared paper, 2023 · strength 0.17
  12. Shunda Wang · 1 shared paper, 2023 · strength 0.17
  13. Dan Li · 1 shared paper, 2023 · strength 0.17
  14. Qinglong Jiang · 3 shared papers, 2016–2017 · strength 0.16
  15. Dongbing Zhao · 3 shared papers, 2016–2017 · strength 0.16
  16. Jie Ma · 2 shared papers, 2017–2018 · strength 0.14
  17. Ye‐Xiong Li · 2 shared papers, 2016–2019 · strength 0.12
  18. Lipeng Zhang · 1 shared paper, 2021 · strength 0.11
  19. Ke Xu · 1 shared paper, 2021 · strength 0.11
  20. Yongxing Du · 1 shared paper, 2021 · strength 0.11
  21. Jin Peng He · 1 shared paper, 2020 · strength 0.11
  22. Fei Li · 1 shared paper, 2019 · strength 0.08
  23. Shengping Li · 1 shared paper, 2019 · strength 0.08
  24. Jing Jin · 1 shared paper, 2019 · strength 0.08
  25. Menghua Dai · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.